Quarterly report pursuant to Section 13 or 15(d)

Collaboration Agreements (Details)

v3.19.3
Collaboration Agreements (Details)
3 Months Ended 9 Months Ended
Sep. 30, 2019
USD ($)
Sep. 30, 2019
USD ($)
Upfront payment   $ 3,000,000
Revenue recognized $ 0 0
Deferred revenue 1,500,000 1,500,000
Amount due 1,500,000 1,500,000
Fixed consideration   3,000,000
RX-3117 License [Member]    
Upfront payment   2,500,000
RX-3117 Clinical Material [Member]    
Upfront payment   500,000
China [Member]    
Milestone payment 126,000,000 126,000,000
Republic of Singapore, China, Hong Kong, Macau and Taiwan [Member]    
Milestone payment $ 100,000,000 $ 100,000,000